Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06646224
NA

Efficacy and Safety of the CorVad Percutaneous Ventricular Assist System in Cardiogenic Shock

Sponsor: Shenzhen Core Medical Technology CO.,LTD.

View on ClinicalTrials.gov

Summary

This study aims to evaluate the safety and effectiveness of the CorVad Percutaneous Ventricular Assist System for providing circulatory support in patients with cardiogenic shock caused by cardiomyopathy. This will be assessed through a prospective, multicenter, single-arm clinical trial involving patients with cardiogenic shock. The focus will be on determining the device's ability to improve survival outcomes and reduce the risk of related adverse events in these patients.

Official title: A Clinical Trial to Evaluate the Efficacy and Safety of the CorVad Percutaneous Ventricular Assist System in the Treatment of Cardiogenic Shock Caused by Cardiomyopathy

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2024-10-12

Completion Date

2025-05-31

Last Updated

2024-10-17

Healthy Volunteers

No

Interventions

DEVICE

CorVad Percutaneous Ventricular Assist System

The CorVad Percutaneous Ventricular Assist System provides circulatory support for patients with cardiogenic shock.

Locations (1)

Fuwai Hospital Chinese Academy of Medical Sciences.Shenzhen

Shenzhen, Guangdong, China